<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496310</url>
  </required_header>
  <id_info>
    <org_study_id>GR-2018-12365475</org_study_id>
    <nct_id>NCT04496310</nct_id>
  </id_info>
  <brief_title>Tele-epic (Telemedicine for Epilepsy Care)</brief_title>
  <acronym>Tele-epic</acronym>
  <official_title>Telemedicine With Mobile Internet Devices for Innovative Care of Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Usl di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Usl di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epilepsy is a chronic condition that requires consistent follow-up aimed at seizure control,&#xD;
      surveillance of comorbidities, monitoring of antiepileptic drugs (AED) levels and side&#xD;
      effects. Patients may encounter difficulties to be assessed adequately and the disease burden&#xD;
      is increased by the need for travelling across the country for medical consultations. Driving&#xD;
      restrictions are a further limit to access specialized Centers able to provide an integrated&#xD;
      approach focused on patient needs. Telemedicine (TM) offers an invaluable support to patient&#xD;
      follow-up, joining the sparse distribution of patients in the country with the prompt&#xD;
      availability of a team of experts. The project assesses, through a randomized controlled&#xD;
      trial, the non-inferiority of TM in monitoring seizure control compared to usual&#xD;
      (face-to-face) care. This approach, coupled with a new self home-sampling method for the&#xD;
      measurement of AED levels, will reduce health care costs and simplify patients management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">July 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizures control through seizure diary</measure>
    <time_frame>3 years</time_frame>
    <description>Non-inferiority in seizures control of follow-up procedures through video consultations with telemedicine devices versus in-office, usual care (UC).&#xD;
Outcomes: non-inferiority of mTM on the primary end-point (seizure control assessed through seizure diary) at 18 month follow- up.&#xD;
Assessment of &quot;seizure control&quot; at the end of 18 month-follow-up. Clinical worsening defined as at least 1: (i) fall of at least 2 positions of the following frequency categories: daily/multiple per day; multiple/week, weekly; multiple/month; monthly; multiple/year; annual; (ii) relapse after SF; (iii) new-onset/relapse of convulsive seizures, tonic/atonic seizures with fall, status epilepticus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Comparing Adherence to treatment (trough anti epileptic drug monitoring) among telemdicne group and usual care group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADRs - Adverse Events Profile-AEP</measure>
    <time_frame>3 years</time_frame>
    <description>Comparing adverse drugs reactions among telemdicne group and usual care group (Adverse Events Profile-AEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>3 years</time_frame>
    <description>Comparing quality of life among telemdicne group and usual care group (QoL In Epilepsy-QOLIE- 31,1.0,)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric quality of life (PedsQL)</measure>
    <time_frame>3 years</time_frame>
    <description>Comparing pediatric quality of life among telemdicne group and usual care group (Pediatric QoL Inventory-PedsQL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood-disorders - Beck Depression</measure>
    <time_frame>3 years</time_frame>
    <description>Comparing the occurence of mood-disorders (Beck Depression Inventory-BDI-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood-disorders - State-Trait Anxiety</measure>
    <time_frame>3 years</time_frame>
    <description>Comparing the occurence of mood-disorders (State-Trait Anxiety Inventory-STAI Y-1,2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood-disorders - Child Behavior</measure>
    <time_frame>3 years</time_frame>
    <description>Comparing the occurence of mood-disorders (Child Behavior CheckList-CBCL for patients aged 6-18 yrs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Epilepsy</condition>
  <condition>Epileptic Encephalopathy</condition>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>Telemedicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline: in office clinical assessment of all patients (collection of seizure diary).&#xD;
Followup: scheduled 6-month consultations through a telemedicine device providing remote outcome assessment, counselling and follow-up. If required, on call video consultations available by contacting a provider through telemedicine, 3-hr/week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Baseline: in office clinical assessment of all patients (collection of seizure diary).&#xD;
Followup: scheduled 6-month in-office consultations with outcome assessment, counselling and follow-up. On-call consultations are possible if needed by the patient, by contacting a clinician through an in-office phone call, 3-hr/week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Telemedicine</intervention_name>
    <description>Telemedicine versus usual care (face to face visit)</description>
    <arm_group_label>Telemedicine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult (age&gt;18 yrs) and pediatric (age&lt;18yrs) outpatients with established diagnosis of&#xD;
             epilepsy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda USL di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>laura licchetta, MD, PhD</last_name>
      <phone>+39 0514966991</phone>
      <email>laura.licchetta2@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda USL di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>laura licchetta, md, phd</last_name>
      <phone>+390514966991</phone>
      <email>laura.licchetta2@unibo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Telemedicine</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Antiepileptic drugs monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

